NASDAQ · SNGX
Healthcare · Biotechnology
$0.36
Down-$0.01 (-3.63%)
Updated Nov 2, 2026, 6:55 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SNGX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
SNGX closed at $0.36 after 20 trading sessions, down 0.86% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $0.3776 | $0.3776 | $0.3361 | $0.3559 | 69.7K |
| Oct 29, 2026 | $0.376 | $0.3776 | $0.3551 | $0.3693 | 36.76K |
| Oct 28, 2026 | $0.3507 | $0.3762 | $0.3507 | $0.3751 | 62.63K |
| Oct 27, 2026 | $0.3516 | $0.3699 | $0.35 | $0.363 | 95.3K |
| Oct 26, 2026 | $0.3693 | $0.3718 | $0.35 | $0.3501 | 47.72K |
| Oct 23, 2026 | $0.35 | $0.37 | $0.338 | $0.365 | 127.88K |
| Oct 22, 2026 | $0.37 | $0.3736 | $0.3526 | $0.3645 | 131.6K |
| Oct 21, 2026 | $0.3401 | $0.368 | $0.3401 | $0.3501 | 69.23K |
| Oct 20, 2026 | $0.344 | $0.3639 | $0.3384 | $0.3546 | 81.15K |
| Oct 19, 2026 | $0.343 | $0.3483 | $0.337 | $0.3437 | 69.76K |
| Oct 16, 2026 | $0.3601 | $0.3619 | $0.346 | $0.3531 | 218.75K |
| Oct 15, 2026 | $0.344 | $0.3551 | $0.3414 | $0.3551 | 172.48K |
| Oct 14, 2026 | $0.3248 | $0.3499 | $0.3248 | $0.3407 | 148.23K |
| Oct 13, 2026 | $0.35 | $0.367 | $0.3313 | $0.3348 | 267.42K |
| Oct 12, 2026 | $0.3636 | $0.3695 | $0.3509 | $0.3517 | 62.1K |
| Oct 9, 2026 | $0.35 | $0.37 | $0.35 | $0.3636 | 114.52K |
| Oct 8, 2026 | $0.36 | $0.3627 | $0.345 | $0.3466 | 120.48K |
| Oct 7, 2026 | $0.36 | $0.3618 | $0.3535 | $0.3535 | 62.82K |
| Oct 6, 2026 | $0.357 | $0.365 | $0.357 | $0.358 | 185.67K |
| Oct 5, 2026 | $0.3606 | $0.37 | $0.357 | $0.359 | 107.9K |
The latest Smart Investors Daily articles mentioning SNGX.
Company
Market Activity
Research & News
SNGX research
Company profile and research snapshot.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 16, 2025 | Alliance Global Partners | Buy | — |
| Dec 4, 2020 | B. Riley FBR | Buy | — |
| Jul 28, 2020 | Dawson James | Neutral | — |
| Jan 31, 2018 | H.C. Wainwright | Neutral | — |
| Aug 14, 2017 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 10, 2026
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced
Yahoo · Feb 26, 2026
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) provided a positive recommendation on the Company's request for orphan drug designation for dusquetide (the active pharmaceutical ingredient in SGX945) for the treatment of Behçet's Dise
Benzinga · Feb 26, 2026
Yahoo · Dec 3, 2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Chronic Rare Diseases in an Aging America: Why HyBryte and F
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SNGX.
